抗风湿药物优化治疗类风湿性关节炎的临床效果比较

目的 探讨在类风湿性关节炎患者的临床治疗过程中,抗风湿药物的联合使用对于该类患者的临床效果.方法 选取2017年1月至12月就诊的类风湿性关节炎患者160例,根据临床治疗方法的不同,分为对照组和联合组.对照组主要给予患者治疗类风湿药物,而联合组在治疗类风湿基础上给予抗风湿治疗.评估两组患者在就诊时、4周时和12周时的疼痛指数、肿胀指数、功能障碍指数以及晨僵次数,并且比较两组患者的不良反应发生情况.结果 两组患者的临床一般资料差异无统计学意义(P>0.05).联合组和对照组患者的疼痛指数、肿胀指数、功能障碍指数以及晨僵次数在就诊时差异均无统计学意义(P>0.05),在4周时,联合组患者的数据均优于对照组,差异均具有统计学意义(P<0.05),在12周时差异均无统计学意义(P>0.05).联合组患者在恶心呕吐、腹痛腹胀、脱发、皮疹、口腔溃疡、感染、失眠、白细胞(WBC)减少以及谷丙转氨酶(ALT)增多方面的不良反应,与对照组比较,差异均无统计学意义(P>0.05).结论 对于类风湿性关节炎的患者,联合抗风湿药物具有较好的治疗效果,值得在临床范围内推广.

Objective To explore the clinical effects of the combined use of anti-rheumatic drugs in the clinical treatment of patients with rheumatoid arthritis.Methods 160 patients with rheumatoid arthritis who were present in our hospital were selected from January 2017 to December 2017,and they were divided into control group and combination group according to different clinical treatment methods.The control group was mainly given to patients to treat rheumatoid drugs,while the combination group was given antirheumatic therapy on the basis of rheumatoid treatment.The pain index,swelling index,dysfunction index,and number of morning stiffness at the time of visit,at 4 weeks,and at 12 weeks were evaluated for the two groups of patients,and the incidence of adverse reactions was compared between the two groups of patients.Results There was no statistical difference in clinical general data between the two groups(P>0.05).There was no statistical difference in the pain index,swelling index,dysfunction index,and number of morning stiffness among the patients in the combination group and the control group(P>0.05).At the 4th week,the data of the combined group were better than that of the control group.There were statistical differences(P<0.05),and there was no statistical difference at 12 weeks(P>0.05).The adverse reactions of patients in the combined group in nausea and vomiting,abdominal pain,bloating,hair loss,rash,mouth ulcer,infection,insomnia,WBC decrease,and ALT increase were not statistically significant compared with the control group(P>0.05).Conclusion For patients with rheumatoid arthritis,the combination of anti-rheumatic drugs has a better therapeutic effect,which is worth promoting in the clinical scope.